Company Overview and News

 
Talend Updates Data Fabric to Unlock Analytics Potential of SAP Data

2018-04-16 globenewswire
REDWOOD CITY, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in cloud and big data integration solutions, today unveiled significant updates to Talend Data Fabric that allow customers to unlock data stored in SAP systems for analytical insights, maximizing their SAP investments. Expanding upon Talend’s current support for SAP, the new capabilities help customers easily and quickly combine existing SAP data with other enterprise applications and external big data sources, then offload it to data lakes or data warehouses—either on-premises or in the cloud—to run big data scenarios.
Upvote Downvote

 
Talend to Report First Quarter Fiscal Year 2018 Financial

2018-04-09 globenewswire
REDWOOD CITY, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ:TLND), a global leader in cloud and big data integration solutions, today announced it will release its financial results for the first quarter ended March 31, 2018, after market close on Thursday, May 10, 2018. The company will host a conference call and live webcast for analysts and investors at 4:30 p.m. Eastern time on that day.
Upvote Downvote

 
Why the Salesforce.com, Inc. Deal With Mulesoft May Be Too Risky

2018-03-29 investorplace
When it comes to acquisitions, salesforce.com, inc. (NASDAQ:CRM) is far from timid. The company’s co-founder and CEO, Marc Benioff, has pulled the trigger on many deals during the past few years. And the results have been mostly positive for the CRM stock price.
Upvote Downvote

1
MuleSoft: A Mule Laden With Gold!

2018-03-26 seekingalpha
Some observers felt that the valuation was excessive at more than 16X forward revenues, a new record, apparently for that metric in the enterprise IT space.
Upvote Downvote

 
TLND / Talend S.A. / SILVER LAKE SUMERU (OFFSHORE) AIV GP, LTD. - SC 13G/A (Passive Investment)

2018-03-15 sec.gov
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
TLND / Talend S.A. / SILVER LAKE SUMERU (OFFSHORE) AIV GP, LTD. - SC 13G/A (Passive Investment)

2018-03-15 sec.gov
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
TLND / Talend S.A. 6-K (Current Report of Foreign Issuer)

2018-03-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

 
TLND / Talend S.A. 424B3 (Prospectus)

2018-03-08 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
Upvote Downvote

 
TLND / Talend S.A. 424B3 (Prospectus)

2018-03-06 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
Upvote Downvote

 
TLND / Talend S.A. TALEND S.A. 6-K (Current Report of Foreign Issuer)

2018-03-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

 
TLND / Talend S.A. 20-F

2018-03-05 sec.gov
tlnd_Current_Folio_20F Table of Contents
Upvote Downvote

 
TLND / Talend S.A. / Capital World Investors - SC 13G (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Talend SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) 874224207 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shal
Upvote Downvote

 
TLND / Talend S.A. / Idinvest Partners - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
    UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549         SCHEDULE 13G   (Amendment No. 2)*   Talend S.A. (Name of Issuer) Ordinary Shares, nominal value €0.08 per share (Title of Class of Securities) 8742242071 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) o Rule 13d-1(c) x Rule 13d-1(d)   *The remainder of this co
Upvote Downvote

 
TLND / Talend S.A. / Idinvest Partners - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
    UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549         SCHEDULE 13G   (Amendment No. 2)*   Talend S.A. (Name of Issuer) Ordinary Shares, nominal value €0.08 per share (Title of Class of Securities) 8742242071 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) o Rule 13d-1(c) x Rule 13d-1(d)   *The remainder of this co
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

12h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 874224207